NCT05817708View on ClinicalTrials.gov

A Study of Silmitasertib (CX-4945) in Healthy Subject

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 28, 2022

Primary Completion Date

March 23, 2023

Study Completion Date

June 20, 2023

Conditions
COVID-19
Interventions
DRUG

CX-4945

"Drug: CX-4945~Silmitasertib, orally, once or twice daily for 5 days.~Other Name: Silmitasertib"

Trial Locations (1)

110301

Taipei Medical University Hospital, Taipei

All Listed Sponsors
lead

Senhwa Biosciences, Inc.

INDUSTRY